Asset

TENAPANOR

Ardelyx Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (9)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02346890phase1completed2013-04-012013-04-01ArdelyxA Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722
NCT02249936phase1completed2013-02-012013-02-01ArdelyxA Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations
NCT01847092phase2completed2013-05-012015-03-01ArdelyxA Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria
NCT02063386phase1completed2014-04-012014-05-01ArdelyxAZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study
NCT02081534phase2completed2014-03-012014-11-01ArdelyxDose Finding Study to Treat High Phosphate Levels in the Blood.

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)